Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration

Eur J Clin Pharmacol

17 July Jul 2023 2 months ago
  • Mapelli M, Mattavelli I, Salvioni E, De Martino F, Mantegazza V, Vignati C, Tamborini G, Agostoni P.

Sacubitril/valsartan is a mainstay of the treatment of heart failure with reduced ejection fraction (HFrEF); however, its effects on exercise performance yielded conflicting results. Aim of our study was to evaluate the impact of sacubitril/valsartan on exercise parameters and echocardiographic and biomarker changes at different drug doses.

Reference: Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.
Mapelli M, Mattavelli I, Paolillo S, Salvioni E, Magrì D, Galotta A, De Martino F, Mantegazza V, Vignati C, Esposito I, Dell'Aversana S, Paolillo R, Capovilla T, Tamborini G, Nepitella AA, Filardi PP, Agostoni P. Eur J Clin Pharmacol. 2023 Jun 27.

Go to PubMed